Varenicline Effects In Schizophrenic Smokers

Nathan Kline Institute for Psychiatric Research

Status and phase: Completed; Phase 4

Conditions: Tobacco Use Disorder; Schizophrenia; Nicotine Dependance

Treatments: Drug: Varenicline

Study type: Interventional

Funder types: Other

Identifiers

NCT00548470

06I/C34-0

Details and patient eligibility

About

This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).

Enrollment: 14 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis
• Recent History of Cigarette smoking
• Ages 18-65

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

14 participants in 1 patient group

varenicline

Experimental group

Description:

open label varenicline 2mg/day

Treatment:

Drug: Varenicline